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HLA and Malignancy-Progress in
Clinical and Biological Research Vol.
16. Eds. G. P. MIJRPHY, E. COHEN, J. E.
FITZPATRICK, D. PRESSMAN. (1977) New
York: Alan R. Liss. 248 pp. U.S.$24.00
net.
This volume reports the proceedings of a
symposium presented by Roswell Park
Memorial Institute, Buffalo, New York, in
August, 1976. Although published with
commendable rapidity it is nevertheless
somewhat overshadowed by more or less
contemporaneous publications covering the
wider aspects of HLA and of disease associa-
tion. In particular, "HLA and Disease" (eds.
Dausset and Svejgaard; Munksgaard, 1977)
and "Histocompatibility" (Snell, Dausset and
Nathenson, Academic Press, 1976) cover the
same general area and much besides. How-
ever, the present volume does serve a useful
purpose in focussing in more detail on malig-
nant disease, and also provides one or two
introductory chapters on HLA background
studies. It is one of the disappointments and
paradoxes of HLA and disease associations
that few convincing associations between
HLA and human malignancies have been
demonstrated; this in spite of the important
role of mouse MHC in determining resistance
and susceptibility to both experimental and
naturally occurring leukaemias. Part of the
problem with human malignancy must of
course be in the genetic heterogeneity of
human populations. Another "procedural"
problem is the necessity for prospective sur-
veys. If an HLA specificity confers, directly
or indirectly, resistance to a particular
malignancy, one would expect a reduced
frequency of the antigen amongst patients
at the time of presentation with their disease.
Conversely, as patients began to die the
"resistance antigen" might be expected to
rise in frequency amongst the survivors. This
sort of study is much more difficult to set up
and takes much longer than a survey of a
mixed group of patients at various stages of
their disease, and the effects of a resistance
gene would be obscured. There is now good
evidence that this occurs in Hodgkin's
disease, acute lymphoblastic leukaemia and
acute myelogeneous leukaemia. The paper
by Falk and Osoba makes this point very
clearly in connection with Hodgkin's disease,
whilst Parrish, Heise and Cooper found results
which are in agreement with those of Oliver,
Klouda and Lawxler and with our own group
in suggesting that HLA-A9, HLA-B12 and
some other HLA antigens confer some degree
of resistance to acute lymphoblastic and
acute myelogeneous leukaemia, and also
improve duration of survival. Similarly, the
paper by Tsuji et al. demonstrated a reduced
frequency of B5 in gastric cancer patients in
Japan. B5 was not found in a prospective
study of patients with trophoblastic malig-
nancy by Mittal, whilst in a different group
of patients with trophoblastic cancer studied
retrospectively, B5 frequency was comparable
to that of controls. This observation under-
lined the difficulty of dealing with samples of
patients obtained in different ways, especially
when HLA typing for elusive antigens like
B5. There are a number of other useful
papers in this volume, in particular a review
of cancer-prone families by Lynch et al., and
"A critical review" of the whole field by
Dausset.
In summary, this is a useful volume for
cancer research workers and has one or two
particularly good papers of general interest.
R. HARRIS
Histological Typing of Testis Tumours
(International Histological Classifica-
tion of Tumours, No. 16) F. K. MOSTOFI
(1977) W.H.O. 40 pp. + 150 transparen-
cies, Book only, SW.fr. 90.00. Book and
transparencies Sw.fr. 285.00 net.
This valuable series continues on its way
(at ever-increasing prices) and now covers
many of the major tumour sites. The volume
on testis tumours is well up to the high stan-
dard of recent volumes in the series. Dr.
Mostofi was co-author of the 1973 A.F.I.P.
volume 'Tumors of the Male Genital Sys-
tem", and the present volume adopts broadly
the same classification. Pathologists accus-
tomed to the British Institute of Urology's
classification of testicular germ-cell tumours
may be disconcerted to find an apparently
different system adopted here. The differences
are not, in fact, very great. Most tumours
that British pathologists -would class as
Malignant Teratoma Intermediate, or Un-
differentiated, are grouped here as Embryonal
Carcinoma, with or without Teratoma. It
has to be admitted that many tumours
labelled as malignant teratoma in the British
system consist entirely ofmalignant epithelial